In a series of medical advancements, Kite Pharma Inc (NASDAQ:KITE) announced positive results for its anti-CD19 treatment used against aggressive non-Hodgkin’s lymphoma. Following the news, the shares of the company have skyrocketed in after-hours trading with 30% increase in its prices. According to a press release issued by Kite Pharma Inc (NASDAQ:KITE) on August 25, 2014,…